Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): a double-blind, randomised, placebo-controlled trial.

The European respiratory journal（2023）

引用 2|浏览43

暂无评分

摘要

Combination of rituximab and MMF was superior to MMF alone in patients with ILD and a NSIP pattern. The use of this combination must consider the risk of viral infection.

查看译文

关键词

interstitial lung disease,rituximab,mofetil combination,ever-ild,double-blind,placebo-controlled

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要